LY404039

Confirm delete?

LY404039

Zoom

Cat No: 18408

Biochemicals - Receptor Pharmacology

LY404039 is a potent agonist of metabotropic glutamate (mGlu) group II receptors mGluR2 and mGluR3 (Kis = 149 and 62 nM, respectively, for recombinant human isoforms).{32438} It displays 100-fold selectivity for mGluR2/3 over ionotropic glutamate rece...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

(1R,?4S,?5S,?6S)?-4-?amino-2-?thiabicyclo[3.1.0]?hexane-?4,?6-?dicarboxylic acid 2,?2-?dioxide

Correlated keywords:

191471-54-2 LY-404039 LY404040 LY-404040 LY-404,039 LY404,039 LY2140023 LY-2140023 human mGluR-2 mGluR-3 metabotropic glutamate receptor mGluR2 mGluR3 mGlu anxiolytic antipsychotic anti-psychotic domperidone dopamine pomaglumetad

Product Overview:
LY404039 is a potent agonist of metabotropic glutamate (mGlu) group II receptors mGluR2 and mGluR3 (Kis = 149 and 62 nM, respectively, for recombinant human isoforms).{32438} It displays 100-fold selectivity for mGluR2/3 over ionotropic glutamate receptors, glutamate transporters, and several other receptors targeted by known anxiolytic and antipsychotic medications.{32438} LY404039 inhibits the binding of domperidone (Item No. 18875) by 15.5% to dopamine D2 receptors (Kd = ~10 nM in vitro), indicating interaction with this receptor.{32439} LY404039 is orally bioavailable and demonstrates antipsychotic and anxiolytic efficacy in several animal models.{32437}

Size	1 mg
Shipping	dry ice
CAS Number	635318-11-5
Molecular Formula	C₇H₉NO₆S
SMILES	O=S1([C@]([C@@H]2C(O)=O)([H])[C@]2([H])[C@@](C(O)=O)(N)C1)=O
Molecular Weight	235,2
Formulation	A crystalline solid
Purity	≥95%
Custom Code	2930.90
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.